• Accueil >
  • Publications >
  • Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival

Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival

11 janv. 2021eLife

DOI : 10.7554/elife.64090

Auteurs

Paul Guilhamon, Charles Chesnelong, Michelle M Kushida, Ana Nikolic, Divya Singhal, Graham MacLeod, Seyed Ali Madani Tonekaboni, Florence MG Cavalli, Christopher Arlidge, Nishani Rajakulendran, Naghmeh Rastegar, Xiaoguang Hao, Rozina Hassam, Laura J Smith, Heather Whetstone, Fiona J Coutinho, Bettina Nadorp, Katrina I Ellestad, H Artee Luchman, Jennifer Ai-wen Chan, Molly S Shoichet, Michael D Taylor, Benjamin Haibe-Kains, Samuel Weiss, Stephane Angers, Marco Gallo, Peter B Dirks, Mathieu Lupien

Résumé

Chromatin accessibility discriminates stem from mature cell populations, enabling the identification of primitive stem-like cells in primary tumors, such as glioblastoma (GBM) where self-renewing cells driving cancer progression and recurrence are prime targets for therapeutic intervention. We show, using single-cell chromatin accessibility, that primary human GBMs harbor a heterogeneous self-renewing population whose diversity is captured in patient-derived glioblastoma stem cells (GSCs). In-depth characterization of chromatin accessibility in GSCs identifies three GSC states: Reactive, Constructive, and Invasive, each governed by uniquely essential transcription factors and present within GBMs in varying proportions. Orthotopic xenografts reveal that GSC states associate with survival, and identify an invasive GSC signature predictive of low patient survival, in line with the higher invasive properties of Invasive state GSCs compared to Reactive and Constructive GSCs as shown by in vitro and in vivo assays. Our chromatin-driven characterization of GSC states improves prognostic precision and identifies dependencies to guide combination therapies.